Reuters logo
BRIEF-Novelion therapeutics says U.S. FDA approved modifications to JUXTAPID REMS program-SEC Filing
January 9, 2017 / 5:23 PM / 9 months ago

BRIEF-Novelion therapeutics says U.S. FDA approved modifications to JUXTAPID REMS program-SEC Filing

Jan 9 (Reuters) - Novelion Therapeutics Inc -

* Novelion Therapeutics Inc- On January 3, U.S. Food and Drug Administration approved modifications to JUXTAPID REMS program

* Novelion Therapeutics Inc - Approved modifications to REMS program must be implemented within 60 calendar days of January 3, 2017 Source text: (bit.ly/2iV03MF) Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below